Table 7.
Univariate Deterministic Sensitivity Analysis
| Parameter | Base Scenario | Sensitivity Analysis Scenario |
|---|---|---|
| Discount on benefits and costs (0–5%)a,b |
3% | 0% 5% |
| Modification of the cost of HSCT (DRG 803: € 61,000.07)c |
€ 46,204.70 | € 61,001.07 |
| Modification of the cost of HSCT (highest cost available: € 110,276.59 )d | € 46,204.70 | € 110,276.59 |
| Utility in the state of complete no remission (0.655)b | 0.780 | 0.655 |
| Different cure point (6.2 years)b,e | 3 years | 6.2 years, derived from the maximum follow-up of patients in RATIFY |
| Different mortality adjustment after the fourth year (=/x2 mortality, general population)b | 15% higher than the general population | Same as the general population. Twice as high as the general population |
| PVL reduction for midostaurin (20-30-40%) | 100% | 60% 70% 80% |
| Modification of 2nd line therapy costs (± 20%) | 100% | 80% 120% |
| Modification of mortality costs (± 20%) | 100% | 80% 120% |
| Replacement of daunorubicin with idarubicinf | Daunorubicin 60mg/m2/day (days 1–3) | Idarubicin 12 mg/m2/day (days 1–3) |
| Modification of non-pharm health costs during 1st line treatment (± 20%) | 100% | 80% 120% |
Notes: aBased on economic evaluation guidelines. bBased on NICE recommendations. cCost of HSCT equivalent to the cost of DRG 803 (“Allogenic bone marrow transplant”). dThe highest cost of allogeneic HSCT found in the available evidence (eSalud).18 eIn keeping with the follow-up time in the RATIFY study. fBased on expert opinion.
Abbreviation: PVL, ex-factory price.